相似文献
1
Progress on new vaccine strategies for the immunotherapy and prevention of cancer.
J Clin Invest. 2004 Jun;113(11):1515-25. doi: 10.1172/JCI21926.
2
Cancer vaccines: between the idea and the reality.
Nat Rev Immunol. 2003 Aug;3(8):630-41. doi: 10.1038/nri1150.
3
Composite peptide-based vaccines for cancer immunotherapy (Review).
Int J Mol Med. 2015 Jan;35(1):17-23. doi: 10.3892/ijmm.2014.2000. Epub 2014 Nov 12.
4
Recent developments in therapeutic cancer vaccines.
Nat Clin Pract Oncol. 2005 Feb;2(2):108-13. doi: 10.1038/ncponc0098.
5
Cellular immunotherapy for cancer: current concepts and clinical perspectives scientific basis and approaches for therapeutic cancer vaccines. Part I.
Clin Oncol (R Coll Radiol). 2004 Aug;16(5):356-65. doi: 10.1016/j.clon.2004.03.013.
6
Peptide-Based Treatment: A Promising Cancer Therapy.
J Immunol Res. 2015;2015:761820. doi: 10.1155/2015/761820. Epub 2015 Oct 19.
7
[Anti-HER2 vaccines: The HER2 immunotargeting future?].
Pathol Biol (Paris). 2011 Jun;59(3):173-82. doi: 10.1016/j.patbio.2009.04.002. Epub 2009 May 28.
8
IL-13 receptor-directed cancer vaccines and immunotherapy.
Immunotherapy. 2012 Apr;4(4):443-51. doi: 10.2217/imt.12.28.
9
Current developments with peptide-based human tumor vaccines.
Curr Opin Oncol. 2009 Nov;21(6):524-30. doi: 10.1097/CCO.0b013e328331a78e.
10
Vaccine therapy for cancer: fact or fiction?
Surg Technol Int. 2004;13:39-47.
引用本文的文献
1
Clinical Applications of the Molecular Landscape of Melanoma: Integration of Research into Diagnostic and Therapeutic Strategies.
Cancers (Basel). 2025 Apr 24;17(9):1422. doi: 10.3390/cancers17091422.
2
Dendritic Cell Cancer Vaccines: A Focused Review.
Methods Mol Biol. 2025;2926:51-56. doi: 10.1007/978-1-0716-4542-0_4.
3
Current Landscape of Therapeutic Cancer Vaccines.
Methods Mol Biol. 2025;2926:1-14. doi: 10.1007/978-1-0716-4542-0_1.
4
Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy.
Vaccines (Basel). 2024 May 5;12(5):498. doi: 10.3390/vaccines12050498.
5
Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.
Med Oncol. 2024 Apr 9;41(5):112. doi: 10.1007/s12032-024-02347-z.
6
Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases.
Biomedicines. 2024 Mar 21;12(3):699. doi: 10.3390/biomedicines12030699.
7
The Apoptotic Potential Activity of Terminalia Brownii Extracts against Various Cancer Cell Lines.
Asian Pac J Cancer Prev. 2023 Aug 1;24(8):2629-2639. doi: 10.31557/APJCP.2023.24.8.2629.
8
Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses.
J Clin Invest. 2020 Feb 3;130(2):774-788. doi: 10.1172/JCI128267.
9
Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
FASEB J. 2019 May;33(5):6596-6608. doi: 10.1096/fj.201802067RR. Epub 2019 Feb 25.
10
Advances in immunotherapy delivery from implantable and injectable biomaterials.
Acta Biomater. 2019 Apr 1;88:15-31. doi: 10.1016/j.actbio.2019.02.016. Epub 2019 Feb 13.
本文引用的文献
1
Molecular alterations in pediatric sarcomas: potential targets for immunotherapy.
Sarcoma. 1998;2(2):77-87. doi: 10.1080/13577149878037.
2
Molecular mechanisms and biological significance of CTL avidity.
Curr HIV Res. 2003 Jul;1(3):287-94. doi: 10.2174/1570162033485230.
3
Immunoregulatory T cells in tumor immunity.
Curr Opin Immunol. 2004 Apr;16(2):157-62. doi: 10.1016/j.coi.2004.01.010.
4
Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
J Exp Med. 2003 Dec 1;198(11):1741-52. doi: 10.1084/jem.20022227.
5
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7. doi: 10.1073/pnas.1533209100. Epub 2003 Jun 25.
6
Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.
Cancer Res. 2003 May 1;63(9):2127-33.
7
Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells.
Mol Ther. 2003 Apr;7(4):498-505. doi: 10.1016/s1525-0016(03)00044-3.
8
Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
J Clin Oncol. 2003 Apr 15;21(8):1562-73. doi: 10.1200/JCO.2003.09.020.
9
Defective CD8 T cell memory following acute infection without CD4 T cell help.
Science. 2003 Apr 11;300(5617):339-42. doi: 10.1126/science.1083317.
10
Requirement for CD4 T cell help in generating functional CD8 T cell memory.
Science. 2003 Apr 11;300(5617):337-9. doi: 10.1126/science.1082305.
Zotero 插件